How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: BMS-986435 (drug), Placebo (other)
How long the study runs: Study runs about 37 months (dates as stated)
About the drug or intervention: BMS-986435 — drug: Specified dose on specified days · Placebo — other: Specified dose on specified days
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 40 Years to 85 Years
Who: All
Number of participants: 227
Started: 2023-11-07
Last checked: 2026-07

Plain English Summary

What is this study?

• Testing a new treatment for heart failure
• Phase2 - 227 participants
• The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF)

Who can take part?

• Ages 40 Years to 85 Years
• Diagnosed with heart failure

Where?

• Harrow - Local Institution - 0063
• North Shields - Local Institution - 0071
• Leeds - Local Institution - 0072
• Bristol - Local Institution - 0101
• +5 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 40 Years - 85 Years
Who can join: All genders

What the study is looking for

✓Inclusion Criteria
✓\- Adult participants with stable, causing symptoms HFpEF with a normal heart pumping ability.
✓Exclusion Criteria
✓Other protocol-defined Inclusion/Exclusion criteria apply.

See the full criteria

Inclusion Criteria \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability. Exclusion Criteria * Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant. * Other protocol-defined Inclusion/Exclusion criteria apply.

Where Is This Study? (9 UK sites)

Local Institution - 0063

Harrow HA1 3UJ, United Kingdom

Local Institution - 0071

North Shields NE29 8NH, United Kingdom

Local Institution - 0072

Leeds LS1 3EX, United Kingdom

Local Institution - 0101

Bristol BS2 8HW, United Kingdom

Local Institution - 0097

Dundee DD1 9SY, United Kingdom

Local Institution - 0075

London SE1 7EH, United Kingdom

Local Institution - 0062

Oxford OX3 9DU, United Kingdom

Local Institution - 0065

Stockton-on-Tees TS19 8PE, United Kingdom

Local Institution - 0064

Wolverhampton WV10 0QP, United Kingdom

Data sourced from ClinicalTrials.gov · Last verified: 2026-07